|Classification and external resources|
|Group:||Group IV ((+)ssRNA)|
Chikungunya (in the Makonde language "that which bends up") virus (CHIKV) is an arthropod-borne virus, of the genus Alphavirus, that is transmitted to humans by virus-carrying Aedes mosquitoes. There have been recent breakouts of CHIKV associated with severe illness.
CHIKV infection causes an illness with symptoms similar to dengue fever, with an acute febrile phase of the illness lasting only two to five days, followed by a prolonged arthralgic disease that affects the joints of the extremities. The pain associated with CHIKV infection of the joints persists for weeks or months, or in some cases years.
Signs and symptoms 
The incubation period of chikungunya disease ranges from one to twelve days, usually two to three. Its symptoms include a fever up to 40 °C (104 °F), a petechial or maculopapular rash of the trunk and occasionally the limbs, and arthralgia or arthritis affecting multiple joints. Other nonspecific symptoms can include headache, conjunctivitis, slight photophobia and partial loss of taste.
Typically, the fever lasts for two days and then ends abruptly. However, other symptoms—namely joint pain, intense headache, insomnia and an extreme degree of prostration—last for a variable period; usually for about five to seven days. Patients have complained of joint pains for much longer time periods; some as long as two years, depending on their age.
Common laboratory tests for chikungunya include RT-PCR, virus isolation, and serological tests.
- Virus isolation provides the most definitive diagnosis, but takes one to two weeks for completion and must be carried out in biosafety level 3 laboratories. The technique involves exposing specific cell lines to samples from whole blood and identifying chikungunya virus-specific responses.
- RT-PCR using nested primer pairs is used to amplify several chikungunya-specific genes from whole blood. Results can be determined in one to two days.
- Serological diagnosis requires a larger amount of blood than the other methods, and uses an ELISA assay to measure chikungunya-specific IgM levels. Results require two to three days, and false positives can occur with infection via other related viruses, such as o'nyong'nyong virus and Semliki Forest virus.
|This section requires expansion. (July 2008)|
Chikungunya virus is indigenous to tropical Africa and Asia, where it is transmitted to humans by the bite of infected mosquitoes, usually of the genus Aedes. Chikungunya virus belongs to alphavirus genus of the Togaviridae family. It is an "Arbovirus" (Ar-arthropod, bo-borne).
CHIK fever epidemics are sustained by human-mosquito-human transmission. The main virus reservoirs are monkeys, but other species can also be affected, including humans.
|This section requires expansion. (March 2008)|
Human epithelial and endothelial cells, primarily fibroblasts and monocyte-derived macrophages, are susceptible to infection. Lymphoid and monocytoid cells, primary lymphocytes and monocytes and monocyte-derived dendritic cells are not susceptible to infection. Viral entry occurs through pH-dependent endocytosis. Infection is cytopathic and associated with the induction of apoptosis in the infected cell.
Infection is highly sensitive to the antiviral activity of type I and II interferon.
Type 1 Interferon 
Upon infection with chikungunya, the host's fibroblasts will produce type 1 (alpha and beta) interferon. Mice that lack the interferon alpha receptor die in 2–3 days upon being exposed to 102 chikungunya PFU, while wild type mice survive even when exposed to as much as 102 PFU of the virus. At the same time, mice that are partially type 1 deficient (IFN α/β +/-) are mildly affected and experience symptoms such as muscle weakness and lethargy. Partidos et al 2011 saw similar results with the live attenuated strain CHIKV181/25 strain. However, rather than dying, the type 1 interferon deficient (IFN α/β -/-) mice were temporarily disabled and the partially type 1 interferon deficient mice did not have any problems. 
Several studies have attempted to find the upstream components of the type 1 interferon pathway involved in the host's response to chikungunya infection. So far, no one knows the chikungunya specific pathogen associated molecular pattern. Nonetheless, IPS-1—also known as Cardif, MAVS, and VISA—has been found to be an important factor. In 2011, White et al found that interfering with IPS-1 decreased the phosphorylation of interferon regulatory factor 3 (IRF3) and the production of IFN-β. Other studies have found that IRF3 and IRF7 are important in an age-dependent manner. Adult mice that lack both of these regulatory factors die upon infection with chikungunya. Neonates, on the other hand, succumb to the virus if they are deficient in one of these factors.
Chikungunya counters the Type I interferon response by producing NS2, a non-structural protein that degrades Rpb and turns off the host cell's ability to transcribe DNA. NS2 interferes with the JAK-STAT signaling pathway and prevents STAT from becoming phosphorylated.
There currently is no licensed vaccine to protect against chikungunya virus. The most effective means of prevention are protection against contact with the disease-carrying mosquitoes and mosquito control. These include using insect repellents with substances such as DEET (N,N-diethyl-meta-toluamide; also known as N,N'-diethyl-3-methylbenzamide or NNDB), icaridin (also known as picaridin and KBR3023), PMD (p-menthane-3,8-diol, a substance derived from the lemon eucalyptus tree), or IR3535. Wearing bite-proof long sleeves and trousers (pants) also offers protection.
In addition, garments can be treated with pyrethroids, a class of insecticides that often has repellent properties. Vaporized pyrethroids (for example in mosquito coils) are also insect repellents. Securing screens on windows and doors will help to keep mosquitoes out of the house. In the case of the day-active Aedes aegypti and Aedes albopictus, however, this will have only a limited effect, since many contacts between the vector and the host occur outside.
Vaccine research 
Early-stage (phases 1 and 2) clinical trials have provided evidence in humans for safety and prophylactic efficacy of candidate vaccines, but these have not been developed further due to shifting research priorities.
There are no specific treatments for chikungunya, and no vaccine is currently available. A Phase II vaccine trial, sponsored by the US Government and published in the American Journal of Tropical Medicine and Hygiene in 2000, used a live, attenuated virus, developing viral resistance in 98% of those tested after 28 days and 85% still showed resistance after one year.
Chloroquine is gaining ground as a possible treatment for the symptoms associated with chikungunya, and as an anti-inflammatory agent to combat the arthritis associated with the virus. A University of Malaya study found that for arthritis-like symptoms not relieved by aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), chloroquine phosphate (250 mg/day) has given promising results. Unpublished studies in cell culture and monkeys show no effect of chloroquine treatment on reduction of chikungunya disease. The fact sheet on chikungunya advises against using aspirin, ibuprofen, naproxen and other NSAIDs that are recommended for arthritic pain and fever.
|This section requires expansion. (March 2008)|
Recovery from the disease varies by age. Younger patients recover within 5 to 15 days; middle-aged patients recover in 1 to 2.5 months. Recovery is longer for the elderly. The severity of the disease as well as its duration is less in younger patients and pregnant women. In pregnant women, no untoward effects are noticed after the infection.
Pedal oedema (swelling of legs) is observed in many patients, the cause of which remains obscure as it is not related to any cardiovascular, renal or hepatic abnormalities.
Chikungunya virus is an alphavirus closely related to the o'nyong'nyong virus, the Ross River virus in Australia, and the viruses that cause eastern equine encephalitis and western equine encephalitis.
Three genotypes of this virus have been described: West African, East/Central/South African and Asian genotypes.
Chikungunya is generally spread through bites from Aedes aegypti mosquitoes, but recent research by the Pasteur Institute in Paris has suggested chikungunya virus strains in the 2005-2006 Reunion Island outbreak incurred a mutation that facilitated transmission by Asian tiger mosquito (Aedes albopictus).
Concurrent studies by arbovirologists at the University of Texas Medical Branch in Galveston, Texas, confirmed definitively that enhanced chikungunya virus infection of A. albopictus was caused by a point mutation in one of the viral envelope genes (E1). Enhanced transmission of chikungunya virus by A. albopictus could mean an increased risk for chikungunya outbreaks in other areas where the Asian tiger mosquito is present. A recent epidemic in Italy was likely perpetuated by A. albopictus.
On 28 May 2009 in Changwat Trang of Thailand where the virus is endemic, the provincial hospital decided to deliver by Caesarean section a male baby from his chikungunya-infected mother, Khwanruethai Sutmueang, 28, a Trang native, to prevent mother-fetus virus transmission. However, after delivering the baby, the physicians discovered the baby was already infected with the virus, and put him into intensive care because the infection had left the baby unable to breathe by himself or to drink milk. The physicians presumed the virus might be able to be transmitted from a mother to her fetus, but without laboratory confirmation.
Viral evolution 
This virus was first identified in Tanzania in the 1953 appears to have evolved from an alphavirus ~1713 AD (95% credible interval: 1573–1843) in Africa. The East/Central/South African (ECSA) and Asian strains diverged within the last 150 years (95% HPD: 1879 to 1927). The extant ECSA strains—which include the first isolate of this virus—evolved between 1924 and 1943.
The Asian group split into two clades: an Indian lineage which has probably become extinct and a Southeast Asian lineage. The Southeast Asian lineage spread from Thailand to Indonesia; and then to the Philippines and more recently Malaysia. The recent Indian Ocean basin outbreak that began in 2004 appears to have originated from the ECSA group back in 2002 (95% credible interval: December 2001 to December 2003).
The estimated overall mutation rate is 4.33 × 10−4 nucleotide substitutions per site per year—a rate similar to those found in other viruses with RNA genomes.
The word chikungunya is thought to derive from a description in the local Makonde dialect, meaning "that which bends up", of the contorted posture of patients afflicted with the severe joint pain and arthritic symptoms associated with this disease. The disease was first described by Marion Robinson and W.H.R. Lumsden in 1955, following an outbreak in 1952 on the Makonde Plateau, along the border between Mozambique and Tanganyika (the mainland part of modern day Tanzania).
According to the initial 1955 report about the epidemiology of the disease, the term chikungunya is derived from the Makonde root verb kungunyala, meaning to dry up or become contorted. In concurrent research, Robinson glossed the Makonde term more specifically as "that which bends up". Subsequent authors apparently overlooked the references to the Makonde language and assumed the term derived from Swahili, the lingua franca of the region. The erroneous attribution of the term as a Swahili word has been repeated in numerous print sources. Many other erroneous spellings and forms of the term are in common use including "chicken guinea", "chicken gunaya", and "chickengunya".
Since its discovery in Tanganyika, Africa, in 1952, chikungunya virus outbreaks have occurred occasionally in Africa, South Asia, and Southeast Asia, but recent outbreaks have spread the disease over a wider range.
Use as a biological weapon 
In popular culture 
See also 
- Chikungunya outbreaks: outbreaks of the disease, 2004 to present
- O'nyong'nyong virus: a similar virus
- Vector (epidemiology)
- Lahariya C, Pradhan SK (December 2006). "Emergence of chikungunya virus in Indian subcontinent after 32 years: a review" (PDF). J Vect Borne Dis 43 (4): 151–60.
- Powers AM, Logue CH (September 2007). "Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus". J. Gen. Virol. 88 (Pt 9): 2363–77. doi:10.1099/vir.0.82858-0. PMID 17698645.
- Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D, Sol-Foulon N, Le Roux K, Prevost MC, Fsihi H, Frenkiel MP, Blanchet F, Afonso PV, Ceccaldi PE, Ozden S, Gessain A, Schuffenecker I, Verhasselt B, Zamborlini A, Saïb A, Rey FA, Arenzana-Seisdedos F, Desprès P, Michault A, Albert ML, Schwartz O (June 2007). "Characterization of reemerging chikungunya virus". PLoS Pathog. 3 (6): e89. doi:10.1371/journal.ppat.0030089. PMC 1904475. PMID 17604450.
- Chhabra M, Mittal V, Bhattacharya D, Rana U, Lal S (2008). "Chikungunya fever: a re-emerging viral infection". Indian J Med Microbiol 26 (1): 5–12. PMID 18227590.
- Vatsal Anand (18 March 2011). "After effects of Chikungunya Fever". Retrieved 2012-06-29.
- Simon F, Parola P, Grandadam M, Fourcade S, Oliver M, Brouqui P, Hance P, Kraemer P, Ali Mohamed A, de Lamballerie X, Charrel R, Tolou H (May 2007). "Chikungunya infection: an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases". Medicine (Baltimore) 86 (3): 123–37. doi:10.1097/MD/0b013e31806010a5. PMID 17505252.
- Taubitz W, Cramer JP, Kapaun A, Pfeffer M, Drosten C, Dobler G, Burchard GD, Löscher T (July 2007). "Chikungunya fever in travelers: clinical presentation and course". Clin. Infect. Dis. 45 (1): e1–4. doi:10.1086/518701. PMID 17554689.
- "Laboratory Diagnosis of Chikungunya Fevers". World Health Organization. Archived from the original on September 8, 2012. Retrieved May 20, 2013.
- "Chikungunya—Fact sheet". European Centre for Disease Prevention and Control. 23 January 2008. Retrieved 2008-03-25.[dead link]
- Schilte, C.; Couderc, T.; Chretien, F.; Sourisseau, M.; Gangneux, N.; Guivel-Benhassine, F.; Kraxner, A.; Tschopp, J. et al. (2010). "Type I IFN controls chikungunya virus via its action on nonhematopoietic cells". Journal of Experimental Medicine 207 (2): 429–442. doi:10.1084/jem.20090851. PMC 2822618. PMID 20123960.
- Couderc, T. R. S.; Chrétien, F.; Schilte, C. M.; Disson, O.; Brigitte, M.; Guivel-Benhassine, F.; Touret, Y.; Barau, G. et al. (2008). "A Mouse Model for Chikungunya: Young Age and Inefficient Type-I Interferon Signaling Are Risk Factors for Severe Disease". PLoS Pathogens 4 (2): e29. doi:10.1371/journal.ppat.0040029. PMC 2242832. PMID 18282093.
- Partidos, C. D.; Weger, J.; Brewoo, J.; Seymour, R.; Borland, E. M.; Ledermann, J. P.; Powers, A. M.; Weaver, S. C. et al. (2011). "Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling". Vaccine 29 (16): 3067–3073. doi:10.1016/j.vaccine.2011.01.076. PMC 3081687. PMID 21300099.
- White, L. K.; Sali, T.; Alvarado, D.; Gatti, E.; Pierre, P.; Streblow, D.; Defilippis, V. R. (2010). "Chikungunya Virus Induces IPS-1-Dependent Innate Immune Activation and Protein Kinase R-Independent Translational Shutoff". Journal of Virology 85 (1): 606–620. doi:10.1128/JVI.00767-10. PMC 3014158. PMID 20962078.
- Rudd, P. A.; Wilson, J.; Gardner, J.; Larcher, T.; Babarit, C.; Le, T. T.; Anraku, I.; Kumagai, Y. et al. (2012). "Interferon Response Factors 3 and 7 Protect against Chikungunya Virus Hemorrhagic Fever and Shock". Journal of Virology 86 (18): 9888–9898. doi:10.1128/JVI.00956-12. PMC 3446587. PMID 22761364.
- Schilte, C.; Buckwalter, M. R.; Laird, M. E.; Diamond, M. S.; Schwartz, O.; Albert, M. L. (2012). "Cutting Edge: Independent Roles for IRF-3 and IRF-7 in Hematopoietic and Nonhematopoietic Cells during Host Response to Chikungunya Infection". The Journal of Immunology 188 (7): 2967–2971. doi:10.4049/jimmunol.1103185. PMID 22371392.
- Akhrymuk, I.; Kulemzin, S. V.; Frolova, E. I. (2012). "Evasion of the Innate Immune Response: The Old World Alphavirus nsP2 Protein Induces Rapid Degradation of Rpb1, a Catalytic Subunit of RNA Polymerase II". Journal of Virology 86 (13): 7180–7191. doi:10.1128/JVI.00541-12. PMC 3416352. PMID 22514352.
- Fros, J. J.; Liu, W. J.; Prow, N. A.; Geertsema, C.; Ligtenberg, M.; Vanlandingham, D. L.; Schnettler, E.; Vlak, J. M. et al. (2010). "Chikungunya Virus Nonstructural Protein 2 Inhibits Type I/II Interferon-Stimulated JAK-STAT Signaling". Journal of Virology 84 (20): 10877–10887. doi:10.1128/JVI.00949-10. PMC 2950581. PMID 20686047.
- Burt, F. J.; Rolph, M. S.; Rulli, N. E.; Mahalingam, S.; Heise, M. T. (2012). "Chikungunya: A re-emerging virus". The Lancet 379 (9816): 662–671. doi:10.1016/S0140-6736(11)60281-X. PMID 22100854.
- Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA (June 2000). "Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218". Am. J. Trop. Med. Hyg. 62 (6): 681–5. PMID 11304054.
- Mahendradas P, Ranganna SK, Shetty R, et al. (February 2008). "Ocular manifestations associated with chikungunya". Ophthalmology 115 (2): 287–91. doi:10.1016/j.ophtha.2007.03.085. PMID 17631967.
- Vanlandingham DL, Hong C, Klingler K, Tsetsarkin K, McElroy KL, Powers AM, Lehane MJ, Higgs S (2005). "Differential infectivities of o'nyong-nyong and chikungunya virus isolates in Anopheles gambiae and Aedes aegypti mosquitoes". Am J Trop Med Hyg 72 (5): 616–21. PMID 15891138.
- Martin Enserink (2007). "Chikungunya: No Longer a Third World Disease". Science 318 (5858): 1860–1. doi:10.1126/science.318.5858.1860. PMID 18096785.
- Powers AM, Brault AC, Tesh RB, Weaver SC (2000). "Re-emergence of Chikungunya and O'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships". J Gen Virol 81 (2): 471–479.
- Martin E (2007). "EPIDEMIOLOGY: Tropical Disease Follows Mosquitoes to Europe". Science 317 (5844): 1485. doi:10.1126/science.317.5844.1485a. PMID 17872417.
- Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S (2007). "A Single Mutation in Chikungunya Virus Affects Vector Specificity and Epidemic Potential". PLoS Pathog 3 (12): e201. doi:10.1371/journal.ppat.0030201. PMC 2134949. PMID 18069894.
- ProMED-mail (2007) Chikungunya virus: genetic change. Archive Number 20071209.3973
- European Centers for Disease Control Report Chikungunya in Italy.
- T Rath (2009). Trang hospital found Chikungunya transmitted from a mother to her foetus, 28 May 2009. Accessed: 29 May 2009.
- Volk SM, Chen R, Tsetsarkin KA, Adams AP, Garcia TI, Sall AA, Nasar F, Schuh AJ, Holmes EC et al. (2010). "Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates". J Virol 84 (13): 6497–6504.
- Centers for Disease Control and Prevention (CDC) (29 September 2006). "Chikungunya fever diagnosed among international travelers—United States, 2005–2006". MMWR Morb. Mortal. Wkly. Rep. 55 (38): 1040–2. PMID 17008866.
- Robinson MC (1955). "An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features". Trans. R. Soc. Trop. Med. Hyg. 49 (1): 28–32. doi:10.1016/0035-9203(55)90080-8. PMID 14373834.
- Lumsden WH (1955). "An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952–53. II. General description and epidemiology". Trans. R. Soc. Trop. Med. Hyg. 49 (1): 33–57. doi:10.1016/0035-9203(55)90081-X. PMID 14373835.
- Carey DE (July 1971). "Chikungunya and dengue: a case of mistaken identity?". J Hist Med Allied Sci 26 (3): 243–62. doi:10.1093/jhmas/XXVI.3.243. PMID 4938938.
- Cherian SS, Walimbe AM, Jadhav SM, Gandhe SS, Hundekar SL, Mishra AC, Arankalle VA (2009). "Evolutionary rates and timescale comparison of chikungunya viruses inferred from the whole genome/E1 gene with special reference to the 2005-07 outbreak in the Indian subcontinent". Infect Genet Evol 9 (1): 16–23. doi:10.1016/j.meegid.2008.09.004. PMID 18940268. Retrieved May 20, 2013.
- "Chemical and Biological Weapons: Possession and Programs Past and Present", James Martin Center for Nonproliferation Studies, Middlebury College, 9 April 2002, accessed 14 November 2008.
Further reading 
- "Chikungunya". European Centre for Disease Prevention and Control. 23 January 2008. Retrieved May 20, 2013.
- Powers AM, Logue CH (2007). "Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus". J Gen Virol 88 (9): 2363–77. doi:10.1099/vir.0.82858-0. PMID 17698645.
- Schuffenecker I, Iteman I, Michault A, et al. (July 2006). "Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak". PLoS Med. 3 (7): e263. doi:10.1371/journal.pmed.0030263. PMC 1463904. PMID 16700631.
- WHO site on disease outbreak news
- Mosquito-borne African virus a new threat to West Update on increasing threat, from Reuters
- Virus Pathogen Database and Analysis Resource (ViPR): Togaviridae